The drug developer will have three significant data readouts for RLY-4008 and RLY-2608. Unfortunately for impatient investors, they're all slated for the second half of the year.

Selecta Biosciences, now Cartesian Therapeutics, is a completely different company with a messy share structure. We've decided to replace it with a larger, more investable biotech stock.

The immune tolerance pioneer hopes to transition from a drug developer into a lean, mean, royalty-paying machine. What happens until then?

The pre-commercial drug developer previously expected to commercialize its lead drug candidate in a rare bile duct cancer ahead of other tumor types, but will now pursue a broader tumor-agnostic approval.

The single-cell analysis and spatial biology leader had racked up an impressive string of legal wins protecting its patent estate. The latest decision has relatively little impact.

The company plans to focus on SEL-212, which it estimates could reach peak annual sales of over $700 million. It has paused most other development activity in the meantime.

The precommercial drug developer has finally deprioritized wholly-owned gene therapy programs. Unfortunately, so have several other drug developers throughout the global landscape.

The ReDiscover study evaluating RLY-2608 demonstrated industry-leading safety and tolerability, but initial efficacy data spooked investors. Wall Street is assuming the asset risks lagging the competitive landscape when combined with the chemotherapy drug fulvestrant.

Solt DB Invest previously assigned a significantly higher probability of success (POS) to the pipeline at Relay Therapeutics than the industry average. We're increasing that metric in our modeling, which results in a higher Margin of Safety range.

Initial data from two late-stage studies suggest SEL-212 can be commercially competitive with Krystexxa and its combination formulation. That increases the value of the royalty stream for Selecta Biosciences – or a financing partner.

The single-cell analysis pioneer ended a frustrating 2022 by launching a new instrument. Although the new Visium platform could re-accelerate growth in 2023, it might mask a bigger problem facing the business stemming from slowing consumables revenue growth.

A favorable study design suggests a positive outcome is likely for the upcoming phase 3 data readout for SEL-212 in early 2023. Here's what it needs to do to compete with Krystexxa.

Immune tolerance is quietly gaining traction in the global industry thanks to efforts from an emerging crop of private startups. The technology stack of Selecta Biosciences, anchored by ImmTOR-IL and Xork, is one of the best positioned.

Solt DB Invest initiates coverage of 10x Genomics, the 10th company in our coverage ecosystem. This article reviews the technology platform, upcoming product launch of Visium, and the valuation risk.

(This is where the idea for Open Coverage was born.) More detailed data for RLY-4008 and a new collaboration with Foundation Medicine (Roche) to develop a companion diagnostic for the asset.

This article explores an abstract for a poster and data presentation at the European Society of Medical Oncology (ESMO) Congress 2022.

Let's circle back around to the Relay Therapeutics pipeline update from June 27.

Some quick thoughts on an update from Relay Therapeutics about preliminary phase 1 clinical data for RLY-4008 (FGFR2).